Annual Report 2007 - 08
  Indian Market
 
 
 
 
 
 
 
  Quality
Managment Discussion & Analysis

MAT IMS-ORG For Apr '08

 
Value in
Rs. Billion
MS%
Growth%
Total Indian Pharma Market*
324
100.0
15
Gastroenterology, Diabetes
80
24.6
14
Antiinfectives (oral, injectables)
65
20.1
15
Cardiology
33
10.2
22
Respiratory System
29
8.9
12
Pain, Muscles and joints
24
7.4
8
Psychiatry and Neurology
22
6.9
14
Skin
18
5.4
12
Blood and Blood forming organs
13
4.1
18
Urology,Sex-Hormones
12
3.8
20
 
(* therapy areas have been renamed for understanding)
Chronic therapy areas continued to appear attractive to companies across the spectrum, as they entered the area, created additional marketing divisions & introduced new products. The first of biotech-based or technically-difficult products from multinationals reached market shortly after international launch. Small regional companies continued their effort to create a foothold in larger cities. Some large companies began to expand their field force for rural markets, more seriously than they did before. Patent challenges continued this year as well, testing the boundaries of what is patentable in the country despite the Indian
 
Patent law leaving little room for incremental innovation to get protection. Since 2005, a new Patent Act has been in place in the country offering international levels of intellectual property protection, but with safeguards to protect patient interest. Yet cases continued to be tried & products filed in the judicial system that would test the patentability. As yet, the products that have reached market are therapeutic analogues or products where current treatments are available, or high value biotech based products that address a limited market, such as specific kinds of cancer. We are open to licensing these kinds of products should we feel we require to.

<< Managment Discussion & Analysis  
  Sun Pharmaceutical Industries Ltd. Acme Plaza, Andheri Kurla Road, Andheri (E), Mumbai - 400 059.
Tel: 91-22-66969696 Fax: 91-22- 2821201